Analysis

PremiumFeatures

Schizophrenia research grapples with trial design hurdles in hunt for new treatments

Placebo response in acute schizophrenia trials has been rising for decades. At the same time, the observed treatment benefit is…

Features

Podcast: Customising clinical trials without increasing patient burden

Interviews

Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo

Comment

How advances in drug discovery are changing the path from research to clinical trials

Features

OCT SoCal 2026: Sound governance and collaboration lead the way as regulation percolates

Projects

Iqirvo for the Treatment of Primary Biliary Cholangitis, US

Features

Podcast: Data beyond a study’s main objective provide strategic insights

PremiumFeatures

OCT SoCal 2026: AI know-how, responsible use, and the virtues in taking ownership

Analysis

How real-world evidence can directly support innovation

Analysis

PPD affects races similarly, inequities lie in mental healthcare

GlobalData Healthcare

Analysis

Psychedelic treatments for mental health: Is there substance behind the hype?

News

Can Elon Musk’s Neuralink be trusted to put chips in your brain?

News

IRA lawsuits will be vital test of US’ ability to regulate pharma market

Analysis

How sovereign wealth funds are affecting industries and macroeconomics

Analysis

How sovereign wealth funds are affecting industries and macroeconomics

Analysis

Why does Kuwait struggle to attract FDI?

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close